| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 21.15 | 48.2% |
| Total Income | 21.15 | 48.2% |
| Expenditure | 33.64 | 54.4% |
| PBT | -14.62 | 44.2% |
| Net Profit | 127.07 | 588.2% |
| OPM | -59.09% | 21.73pp |
| NPM | 100.00% | 163.81pp |
| EPS | 0.33 | 571.4% |
Standard BioTools Reports Q1 2026 Revenue of $21.1 Million, Up 5% YOY
06 May 2026 · 6 May, 1:45 am
Summary
Standard BioTools Inc. announced financial results for the quarter ended March 31, 2026. First quarter revenue was $21.1 million, a 5% increase year-over-year. The company reported a 78% improvement in adjusted EBITDA, reducing the loss to $3.1 million. Standard BioTools continues to expect revenue in the range of $80 million to $85 million for fiscal year 2026.
Key Highlights
- 1
Standard BioTools reported first quarter 2026 revenue of $21.1 million.
- 2
The company saw a 54% reduction in operating loss year-over-year.
- 3
Adjusted EBITDA improved by 78% year-over-year, supporting the path to positive adjusted EBITDA exiting 2026.
- 4
Consumables revenue increased by 35% year-over-year to $11.0 million in the first quarter of 2026.
- 5
The company's cash and investments totaled $524 million as of March 31, 2026, excluding a $25 million earnout received after quarter end.
- 6
Net loss for the first quarter of 2026 was $14.6 million, compared to a net loss of $23.4 million in the first quarter of 2025.
Management Comments
Michael Egholm
PhD
“We delivered a strong start to 2026, with first quarter performance coming in above expectations,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “We are operating our base business with consistency, delivering year-over-year top-line growth, and our cost savings initiatives are taking hold with a 78% improvement in adjusted EBITDA to a loss of $3.1 million in the quarter, reinforcing our path to profitability in 2026.” Dr. Egholm continued, “With the sale of SomaLogic to Illumina complete, we are fully focused on strategic capital deployment to transform the business. Our strong balance sheet, with approximately $550 million in cash and investments inclusive of a $25 million earnout received after quarter end, provides substantial flexibility to pursue attractive opportunities and create shareholder value.”
Informational and educational content only. Not investment advice.